<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03104010</url>
  </required_header>
  <id_info>
    <org_study_id>GenSci 034 CT</org_study_id>
    <nct_id>NCT03104010</nct_id>
  </id_info>
  <brief_title>A Non-inferiority Phase 2 Study to Evaluate the Safety and Efficacy of PEG-rhGH in the Treatment of AGHD</brief_title>
  <official_title>A Non-inferiority Phase 2 Study to Evaluate the Safety and Efficacy of PEG-rhGH in the Treatment of Adult Growth Hormone Deficiency (AGHD)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>GeneScience Pharmaceuticals Co., Ltd.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Peking Union Medical College Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Peking University First Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Hebei General Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>The Second Hospital of Hebei Medical University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Qilu Hospital of Shandong University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Second Affiliated Hospital, School of Medicine, Zhejiang University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>The First Affiliated Hospital of Soochow University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>First Affiliated Hospital of Chongqing Medical University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Chongqing Three Gorges Central Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>West China Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>GeneScience Pharmaceuticals Co., Ltd.</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study aims to explore the optimal dose of PEG-rhGH injection in the treatment of AGHD,
      preliminarily evaluate its safety and efficacy, to provide scientific and reliable evidence
      for the medication dosage in Phase 2 clinical study.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Anticipated">April 2017</start_date>
  <completion_date type="Anticipated">September 2022</completion_date>
  <primary_completion_date type="Anticipated">February 2022</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Fat mass change</measure>
    <time_frame>52 weeks</time_frame>
    <description>Change from baseline in fat mass (torso) (FM): FM at the end of treatment minus the baseline value</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Lean body mass change</measure>
    <time_frame>52 weeks</time_frame>
    <description>Change from baseline in lean body mass (LBM): LBM at the end of treatment minus the baseline value</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Blood lipid change</measure>
    <time_frame>52 weeks</time_frame>
    <description>Change from baseline in blood lipid: blood lipid at the end of treatment minus the baseline value</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Waist circumference change</measure>
    <time_frame>52 weeks</time_frame>
    <description>Change from baseline in waist circumference: waist circumference at the end of treatment minus the baseline value</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of body fat change</measure>
    <time_frame>52 weeks</time_frame>
    <description>Change from baseline in the percentage of body fat: TBF at the end of treatment minus the baseline value</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cardiac function change</measure>
    <time_frame>52 weeks</time_frame>
    <description>Change from baseline in cardiac function: ejection fraction at the end of treatment minus the baseline value</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cardiac structure change</measure>
    <time_frame>52 weeks</time_frame>
    <description>Change from baseline in cardiac structure: left ventricular mass at the end of treatment minus the baselines value</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>IGF-1 change</measure>
    <time_frame>52 weeks</time_frame>
    <description>Changes from baseline in IGF-1: IGF-1 SDS at the end of treatment minus the baseline value</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Grip change</measure>
    <time_frame>52 weeks</time_frame>
    <description>Changes from baseline in grip: grip at the end of treatment minus the baseline value, the method of assessment is measurement.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Quality of life change</measure>
    <time_frame>52 weeks</time_frame>
    <description>Changes from baseline in quality of life (QOL): changes in QOL scores before and after treatment</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Waist-hip ratio change</measure>
    <time_frame>52 weeks</time_frame>
    <description>Changes from baseline in waist-hip ratio: changes of waist-hip ratio before and after treatment</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cardiac structure change</measure>
    <time_frame>52 weeks</time_frame>
    <description>Change from baseline in cardiac structure: carotid intima media thickness at the end of treatment minus the baselines value</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">180</enrollment>
  <condition>Adult Growth Hormone Deficiency</condition>
  <arm_group>
    <arm_group_label>PEG-rhGH-1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Pegylated recombinant human growth hormone injection, 12IU/2.0mg/1.0ml/bottle. The first stage, 1-2mg/2-4mg, subcutaneous injection,weekly, 26 weeks.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>PEG-rhGH-2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Pegylated recombinant human growth hormone injection, 12IU/2.0mg/1.0ml/bottle. The second stage (extension period study), maximum ≤4mg/w (24IU/w), 52 weeks.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Somatropin Injection</intervention_name>
    <description>Recombinant human growth hormone injection, 15IU/5mg/3ml/bottle. The first stage , 0.17mg/d(0.5IU/d), subcutaneous injection ,daily, 26weeks. The second stage(extension period study), 0.17mg/d(0.5IU/d), maximum ≤0.68mg/d (2IU/w),52 weeks.</description>
    <arm_group_label>PEG-rhGH-1</arm_group_label>
    <arm_group_label>PEG-rhGH-2</arm_group_label>
    <other_name>Recombinant human growth hormone injection</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Before the treatment, the subject should be diagnosed as AGHD based on medical
             history, clinical symptoms, vital signs, insulin tolerance test and imagological
             examinations.

               -  The subject is diagnosed as GHD during childhood and remains as GHD in adulthood,
                  and the linear growth has completed: bone age (BA) ≥18 years old; or the AGHD
                  patient who experiences paroxysm after 18 years old: such as patients who have
                  experienced pituitary surgeries (2 years after pituitary adenoma surgery, 5 years
                  after craniopharyngioma surgery and 12 months after other pituitary surgeries),
                  traumatic brain injury (TBI), Sheehan syndrome, and etc..

               -  The plasma GH concentration peak is &lt;5ng/ml in insulin tolerance test (ITT) (it's
                  unnecessary to conduct ITT in the following conditions: anterior pituitary
                  dysfunction, pituitary hormone deficiency (more than 3 hormones) and serum IGF-1
                  level below lower limit of normal value: i.e. -2 SD).

          -  Age: 18-60 years old.

          -  Patients with no history of GH treatment for more than one year.

          -  Body mass index (BMI): 18.5 kg/m2≤BMI≤30kg/m2.

          -  When there is other hormones deficiency (such as glucocorticoids, thyroid hormones and
             sex steroids), the subject should have received other hormone replacement therapies
             and the therapeutic dose shall be stable within 3 months before the enrolment.

          -  The subject agrees to cooperate and complete the concerted trial procedures such as
             follow-ups, treatment plan and laboratory examinations, and sign the written informed
             consent.

        Exclusion Criteria:

          -  Patients with serious heart diseases, including NYHA III or above, serious arrhythmia,
             unstable angina pectoris or myocardial infarction within the latest 6 months.

          -  Patients with a history of ischemic cerebrovascular disease, febrile convulsion and
             epilepsy seizures.

          -  Patients with carpal tunnel syndrome.

          -  Patients with poor hypertension control (systolic pressure&gt;140mmHg or diastolic
             pressure &gt;90mmHg under treatment).

          -  Patients with previous or present history of malignant tumor: two or more direct
             relatives within three generations have previous or present history of tumor.

          -  Patients undergoing anti-depressive therapy, immunosuppressive therapy, chemotherapy
             and radiotherapy (or with a history of radiotherapy).

          -  Patients who have ever taken antiobesity drug within the latest 3 months.

          -  Patients with serious infection.

          -  Patients with consciousness disorders and mental diseases.

          -  Subjects with impaired glucose regulation (IGR) (impaired fasting glucose (IFG) and/or
             impaired glucose tolerance (IGT) ) or diabetes; patients with a family history of
             diabetes (direct relatives).

          -  Subjects with abnormal liver and kidney functions (ALT &gt; 2 times of upper limit of
             normal value; eGFR calculated by MDRD formula &lt;60).

          -  Subjects positive for anti-HBc, HBsAg or HBeAg in Hepatitis B virus tests.

          -  Subjects with highly allergic constitution or allergy to proteins or investigational
             productorits excipient in this study.

          -  Subjects who took part in other clinical trials within 3 months.

          -  Patients with other mental or physical deficiencies that influence the evaluation of
             investigational product.

          -  Pregnant or lactating women; females planning to get pregnant within one year.

          -  Subjects whose tumor markers exceed the upper limit of normal range and the
             re-examination result is still high.

          -  Other conditions which is unsuitable for the study in the opinion of the investigator.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>60 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Hui Pan, Doctor</last_name>
    <role>Principal Investigator</role>
    <affiliation>Peking Union Medical College Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Xiaohua Feng, MD</last_name>
    <phone>0431-85170552</phone>
    <email>fengxiaohua@gensci-china.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>The Second Hospital of Hebei Medical University</name>
      <address>
        <city>Shijiazhuang</city>
        <state>Hebei</state>
        <zip>050000</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Songjun Zhang, Doctor</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Heibei General Hospital</name>
      <address>
        <city>Shijiazhuang</city>
        <state>Hebei</state>
        <zip>050057</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>The Affiliated hospital of soochow University</name>
      <address>
        <city>Suzhou</city>
        <state>Jiangsu</state>
        <country>China</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Qilu Hospital of Shandong University</name>
      <address>
        <city>Jinan</city>
        <state>Shandong</state>
        <country>China</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Ling Jiang, Doctor</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>West China Hospital, Sichuan University</name>
      <address>
        <city>Chengdu</city>
        <state>Sichuan</state>
        <country>China</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Zhenmei An, Doctor</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>The Second Affiliated Hospital of Zhejiang University school of medicine</name>
      <address>
        <city>Hangzhou</city>
        <state>Zhejiang</state>
        <country>China</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Wei Gu, Doctor</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Peking Union Medical College Hospital</name>
      <address>
        <city>Beijing</city>
        <zip>100730</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Hui Pan, Doctor</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Chongqing Three Gorges Central Hospital</name>
      <address>
        <city>Chongqing</city>
        <country>China</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Yong Luo, Doctor</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>The First Affiliated Hospital of Chongqing Medical University</name>
      <address>
        <city>Chongqing</city>
        <country>China</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Wei Ren, Doctor</last_name>
    </contact>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>March 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>March 28, 2017</study_first_submitted>
  <study_first_submitted_qc>March 31, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">April 7, 2017</study_first_posted>
  <last_update_submitted>March 31, 2017</last_update_submitted>
  <last_update_submitted_qc>March 31, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">April 7, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Endocrine System Diseases</mesh_term>
    <mesh_term>Dwarfism, Pituitary</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hormones</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

